Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Pharmaceutical companies raised the price of 245 drugs between January 20 and June 20, according to a new analysis by Patients for Affordable Drugs.

Between the lines: Some of these drugs are directly related to the pandemic. And the hikes occurred against the backdrop of economic calamity hitting many American families.

  • The average price increase was 23.8%.

By the numbers: 61 of the drugs with price hikes were being used to treat the coronavirus, while another 30 were undergoing clinical trials for use against it.

  • Some of the drugs — like those used to sedate ventilated patients — saw both a surge in demand and an increase in price.
  • "Although some price hikes may be attributable to interruptions in global manufacturing supply chains, others can be attributed to opportunistic hikes in the face of steep increases in demand," the authors write.

Another 118 drugs that saw price increases are used to manage chronic conditions.

  • These patients are generally more vulnerable to severe coronavirus infections, and thus may be facing harder decisions about returning to work.

Go deeper: Brand-name prescription drug prices have spiked since 2007

Go deeper

The industries that won’t recover without a vaccine

Illustration: Annelise Capossela/Axios

Industries that were once expected to recover after the initial coronavirus lockdowns lifted are now unlikely to bounce back until a vaccine arrives.

Why it matters: In the absence of a widely-adopted vaccine, businesses in the entertainment, travel, restaurant and other industries are struggling to overcome consumer skepticism around indoor activities — even with new safety protocols in place.

Updated Nov 10, 2020 - World

In photos: Coronavirus restrictions grow across Europe

A waiter stands on an empty street in downtown Lisbon on Nov. 9, after Portugal introduced a night-time curfew for 70% of the population, including the capital and also the coastal city of Porto. It'll last for at least two weeks, per the BBC. Photo: Patricia De Melo Moreira/AFP via Getty Images

Portugal and Hungary have become the latest European countries to impose partial lockdowns, with curfews going into effect overnight. Governments across the continent are imposing more restrictions in attempts to curb COVID-19 spikes.

The big picture: Over 9.2 million cases have been reported to the European Centre for Disease Control. Per the ECDC, France has the most (almost 1.8 million) followed by Spain (over 1.3 million) and the United Kingdom (nearly 1.2 million). The COVID death rate per 100,000 of the population is highest in the Czech Republic (25), followed by Belgium (19) and Hungary (10.4).